Compare · MDT vs QTI
MDT vs QTI
Side-by-side comparison of Medtronic plc. (MDT) and QT Imaging Holdings Inc. (QTI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and QTI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.51B, about 2792.7x QTI ($38.1M).
- Over the past year, MDT is down 9.6% and QTI is down 51.3% - MDT leads by 41.8 points.
- MDT has been more active in the news (4 items in the past 4 weeks vs 1 for QTI).
- MDT has more recent analyst coverage (25 ratings vs 0 for QTI).
- Company
- Medtronic plc.
- QT Imaging Holdings Inc.
- Price
- $83.19+1.43%
- $2.91-4.59%
- Market cap
- $106.51B
- $38.1M
- 1M return
- +3.82%
- -23.42%
- 1Y return
- -9.57%
- -51.34%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026
- Medtronic to announce financial results for its first quarter of fiscal year 2027
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
Latest QTI
- QT Imaging Announces Successful Completion of First FDA Routine Inspection with Zero Form 483 Observations
- SEC Form DEF 14A filed by QT Imaging Holdings Inc.
- QT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week
- A New Standard of Reproducibility for Quantitative Biomarkers in Breast Imaging
- SEC Form PRE 14A filed by QT Imaging Holdings Inc.
- QT Imaging Receives Saudi Arabia FDA Regulatory Clearance
- QT Imaging Set to Join the Russell Microcap® Index
- QT Imaging Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- QT Imaging Holdings Announces Closing of $10 Million Underwritten Public Offering
- SEC Form 424B5 filed by QT Imaging Holdings Inc.